On May 29, 2025, HC Wainwright & Co. reaffirmed its position on DiaMedica Therapeutics (DMAC, Financial), maintaining a 'Buy' rating. Analyst Matthew Caufield reiterated this status with an unchanged price target of $10.00 USD.
The decision to reiterate the 'Buy' rating reflects steady confidence in DiaMedica Therapeutics (DMAC, Financial) as the price target has remained consistent at $10.00, aligning with prior evaluations. The stable price target suggests no significant change in the company's outlook or valuation assessments.
Investors in DiaMedica Therapeutics (DMAC, Financial) may find reassurance in this consistent evaluation, which underscores HC Wainwright & Co.'s sustained bullish perspective on the company's potential performance in the market.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 3 analysts, the average target price for DiaMedica Therapeutics Inc (DMAC, Financial) is $9.67 with a high estimate of $11.00 and a low estimate of $8.00. The average target implies an upside of 132.37% from the current price of $4.16. More detailed estimate data can be found on the DiaMedica Therapeutics Inc (DMAC) Forecast page.
Based on the consensus recommendation from 4 brokerage firms, DiaMedica Therapeutics Inc's (DMAC, Financial) average brokerage recommendation is currently 1.8, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
